Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 8/20 | 0.59 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | APAF1 | O14727 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | MGAM | O43451 | 1/20 | 0.46 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SI | P14410 | 1/20 | 0.46 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30467198 | 0.84 | SLC9A1 (0.63) | SLC9A1GRM2RAB9ANPC1MAPT | |
| SCHEMBL1675731 | 0.84 | SLC9A1 (0.63) | SLC9A1GRM2RAB9ANPC1MAPT | |
| SCHEMBL30965604 | 0.82 | SLC9A1 (0.56) | SLC9A1GRM2RAB9ANPC1MAPT | |
| SCHEMBL25034669 | 0.82 | SLC9A1 (0.56) | SLC9A1GRM2RAB9ANPC1MAPT | |
| SCHEMBL26814667 | 0.81 | SLC9A1 (0.55) | SLC9A1GRM2RAB9ANPC1MAPT | |
| SCHEMBL283984 | 0.80 | SLC9A1 (0.65) | SLC9A1GRM2RAB9ANPC1MAPT | |
| SCHEMBL3343750 | 0.78 | SLC9A1 (0.57) | SLC9A1GRM2RAB9ANPC1MAPT | |
| SCHEMBL15339462 | 0.78 | SLC9A1 (0.53) | SLC9A1GRM2RAB9ANPC1MAPT | |
| SCHEMBL30938327 | 0.77 | SLC9A1 (0.54) | SLC9A1GRM2RAB9ANPC1MAPT | |
| SCHEMBL29260063 | 0.77 | SLC9A1 (0.54) | SLC9A1GRM2RAB9ANPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9023860-B2 | Pro-drugs for controlled release of biologically active compounds | SIGNATURE THERAPEUTICS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-9023860-B2 | Pro-drugs for controlled release of biologically active compounds | SIGNATURE THERAPEUTICS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-9023860-B2 | Pro-drugs for controlled release of biologically active compounds | SIGNATURE THERAPEUTICS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| WO-2013004984-A1 | TRICYCLIC COMPOUNDS FOR USE AS KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2013-01-10 | — | — | WO | disclosed |
| US-20090137618-A1 | PRO-DRUGS FOR CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS | 3I, LP | 2009-05-28 | — | — | US | disclosed |
| US-20090137618-A1 | PRO-DRUGS FOR CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS | 3I, LP | 2009-05-28 | — | — | US | disclosed |
| US-20090137618-A1 | PRO-DRUGS FOR CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS | 3I, LP | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137618-A1 | PRO-DRUGS FOR CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS | CRH, FURIN, PEPD | SLC9A1 2833/4885GRM2 2722/4885RAB9A 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.